Lenvatinib. an oral small-molecule multiple tyrosine kinase inhibitor (TKI). has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC). Proteinuria is one of the most common adverse events associated with lenvatinib treatment. https://halohealthcarers.shop/product-category/homecare/